Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-ICT: Toripalimab in LA-HNSCC
NCT06647563Phase 3Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Nov 2024
- Primary completion
- Sep 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of toripalimab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Shanghai Ninth People's Hospital. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT06647563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647563.